[1]刘小娜,郝 娜,马晓霞,等.三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌临床研究[J].陕西中医杂志,2021,(10):1367-1370.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.010]
　LIU Xiaona,HAO Na,MA Xiaoxia,et al.Study of Sanhuang decoction combined with pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple negative breast cancer[J].,2021,(10):1367-1370.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.010]
点击复制

三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌临床研究
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年10期
页码:
1367-1370
栏目:
临床研究
出版日期:
2021-10-05

文章信息/Info

Title:
Study of Sanhuang decoction combined with pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple negative breast cancer
作者:
刘小娜; 郝 娜; 马晓霞; 周瑜辉; 汤小江
(西安交通大学第一附属医院乳腺外科,陕西 西安 710061)
Author(s):
LIU Xiaona; HAO Na; MA Xiaoxia; ZHOU Yuhui; TANG Xiaojiang
(Department of Breast Surgery,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
关键词:
三阴乳腺癌;  三黄煎剂;  吡柔比星;  多西他赛;  环磷酰胺;  新辅助化疗
Keywords:
Triple negative breast cancer;  Sanhuang decoction;  Pirarubicin;  Docetaxel;  Cyclophosphamide;  Neoadjuvant chemotherapy
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7369.2020.10.010
文献标志码:
A
摘要:
目的:探究三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌的临床疗效。方法:选取三阴乳腺癌患者148例,随机分为对照组和研究组,每组74例。对照组给予吡柔比星、多西他赛、环磷酰胺新辅助化疗,研究组在对照组基础上联合三黄煎剂进行治疗,记录两组治疗后的临床疗效,随访2年的总生存期(OS)、无进展生存期(PFS)及Kamofsky评分,检测两组治疗前后免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平,以及记录两组治疗期间不良反应的发生情况。结果:研究组治疗后的总缓解率、总控制率均比对照组高(P<0.05); 治疗后,研究组CD3+、CD4+、CD4+/CD8+水平均比对照组的更高(P<0.05),CD8+水平比对照组更低(P<0.05); 两组OS、PFS比较差异无统计学意义(P>0.05),但研究组Kamofsky评分比对照组高(P<0.05); 治疗期间,研究组的不良反应发生率比对照组低(P<0.05)。结论:三黄煎剂联合吡柔比星、多西他赛、环磷酰胺新辅助化疗治疗三阴乳腺癌能提高临床疗效,增强免疫力,改善预后,用药安全性更高。
Abstract:
Objective:To explore the clinical efficacy of Sanhuang decoction combined with pirubicin,docetaxel,and cyclophosphamide for neoadjuvant chemotherapy in the treatment of triple-negative breast cancer(TNBC).Methods:A total of 148 TNBC patients were randomly divided into control group and study group,74 cases in each group.The control group was given pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy,while study group was treated with Sanhuang decoction on basis of control group.The clinical curative effect after treatment,overall survival(OS)of 2-year follow-up,progression-free survival(PFS)and Kamofsky scores in both groups were recorded.The levels of immune indexes(CD3+,CD4+,CD8+,CD4+/CD8+)in both groups before and after treatment were detected.The occurrence of adverse reactions during treatment in both groups was recorded.Results:After treatment,total remission rate and total control rate were higher in study group than control group(P<0.05).After treatment,levels of CD3+,CD4+ and CD4+/CD8+were higher in study group than control group(P<0.05),while CD8+ level was lower in study group(P<0.05).There was no significant difference in OS or PFS between the two groups(P>0.05).Kamofsky score was higher in study group than control group(P<0.05).During treatment,incidence of adverse reactions was lower in study group than control group(P<0.05).Conclusion:Sanhuang decoction combined with pirarubicin,docetaxel and cyclophosphamide for neoadjuvant chemotherapy in treatment of TNBC can improve clinical curative effect,enhance immunity,and improve prognosis,with higher medication safety.

参考文献/References:

[1] 马少君,刘延梅,康晓丽,等.三阴性乳腺癌雄激素受体表达与X线和超声影像特征关系研究[J].陕西医学杂志,2020,49(12):1584-1588.
[2] 王 艳,张年庆,彭德峰,等.三阴乳腺癌的危险因素和临床病理特征分析[J].中华全科医学,2017,15(6):930-933.
[3] Earl H,Hiller L,Dunn JA,et al.Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil,epirubicin and cyclophosphamide,for women with HER2 negative early breast cancer:ART emis trial[J].Annals of Oncology,2017,28(8):1817-1824.
[4] 卞卫和,陈佳静,唐 甜,等.三黄煎剂改善乳腺癌患者慢性应激状态30例临床研究[J].时珍国医国药,2017,28(10):2458-2460.
[5] 赵淑红,曹席明,于 娇,等.转移性三阴乳腺癌89例临床特点及生存分析[J].陕西医学杂志,2016,45(7):859-861.
[6] 吴心力,高雅静,卢雯平.三阴乳腺癌的证型分布规律探讨[J].国际中医中药杂志,2013,35(1):11-14.
[7] 邵 帅,李培峰,柳玉彬,等.乳腺癌新辅助化疗疗效评价体系[J].现代生物医学进展,2012,12(25):4964-4969.
[8] 赵甡慧,李文妍,王亚红,等.紫杉醇联合卡铂对于晚期三阴性乳腺癌治疗效果分析[J].中国医学创新,2018,445(19):21-24.
[9] 马宇光,赵 芳,王 梦,等.三阴性乳腺癌术后骨转移与血清PRL、IL-1β以及BSP表达之间的关联探索[J].中南医学科学杂志,2020,48(4):403-405.
[10] 张志强,时 莎,刘丽丽,等.局部区域复发乳腺癌预后相关临床因素分析[J].中国临床实用医学,2017,8(3):26-33.
[11] Wang S,Xue W,Zhao X,et al.Effects of docetaxel and epirubicin combined with cyclophosphamide on clinical efficacy and tumor markers of breast cancer patients with different molecular types[J].China Pharmacy,2017,28(23):3212-3216.
[12] 张栓宝,张燕平,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,40(11):80-83.
[13] 陈佳静,姚 昶.三黄煎剂干预绝经后激素受体阳性乳腺癌患者慢性应激状态临床研究[J].辽宁中医药大学学报,2018,20(4):149-152.
[14] 李子良,蔡铭泉,吴 丹.三阴乳腺癌患者新辅助化疗疗效及预后评价[J].中国肿瘤临床与康复,2017,24(1):43-45.
[15] 李 一,黄 婷,杨麟瀚,等.鸦胆子油乳注射液联合多西他赛和吡柔比星及环磷酰胺治疗晚期乳腺癌的临床效果[J].中国医药,2020,15(9):93-96.
[16] 薛文武,谭婷婷.中医辨证治疗乳腺癌疗效及对患者癌症指标的影响研究[J].陕西中医,2018,39(3):338-340.
[17] 张曦平,王 聪,王倩雯,等.三黄煎剂对乳腺癌患者机体慢性应激状态及血液黏稠状态的改善作用[J].中国肿瘤外科杂志,2020,12(6):534-538.
[18] 宋 凯.黄芪提取物对乳腺癌细胞增殖的抑制作用机制[J].基因组学与应用生物学,2020,39(8):372-376.
[19] 亓小改,韩 翔,郝娟芝,等.姜黄素抑制乳腺癌细胞增殖与侵袭机制探讨[J].中华肿瘤防治杂志,2018,25(17):1211-1216.
[20] 高 兆,夏 猛.外泌体在肿瘤诊断和治疗中的作用研究概况[J].辽宁中医杂志,2018,45(6):1332-1335.
[21] 许岩磊,叶小舟,唐 甜,等.三黄煎剂改善乳腺癌患者围手术期炎症反应的研究[J].中国临床研究,2017,30(2):259-262.

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2021SF-010)
更新日期/Last Update: 2021-10-09